Patents by Inventor Jun-Sub Choi

Jun-Sub Choi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190388399
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating AIDS, comprising a rhodanine derivative and a nucleoside reverse transcriptase inhibitor. A complex composition of the present invention exhibits a synergistic effect in terms of anti-HIV activity as compared with a case where each of the compounds is used as a single drug. Thus, the composition provides sufficient anti-HIV activity and exhibits an excellent effect of decreasing side effects such as toxicity even in a case where each compound is administered in a small amount. Accordingly, the present invention is expected to greatly contribute to treatment of AIDS patients.
    Type: Application
    Filed: August 29, 2019
    Publication date: December 26, 2019
    Inventors: Min Jung KIM, Jun Sub CHOI, Hye Cheong KOO, Yi Yong BAEK
  • Patent number: 10497487
    Abstract: In a transparent electrode based on a metal material having reduced light reflectance, a light absorbing layer having black characteristic is formed on a lower surface, a partition wall, and/or an upper surface of a metal wire, and thus, light reflectance of transparent electrode is minimized. In a method of manufacturing a transparent electrode, the light absorbing layer can be selectively formed on the upper and lower surfaces and the partition wall of the metal wire having a fine line width by using self-aligning and a spontaneous pattern effect. A conductive wire is implemented by using an imprinting process using an elastic body-based stamp, and thus, conductive wires having a fine line width and an excellent aspect ratio can be formed, so that it is possible to improve electric conductivity and transmittance.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: December 3, 2019
    Assignee: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Hak-Rin Kim, Ji-Sub Park, Jun-Chan Choi
  • Patent number: 10485786
    Abstract: The present invention provides a pharmaceutical composition for preventing or treating macular degeneration, which comprises benzopyran derivatives substituted with secondary amines including imidazole or pharmaceutically acceptable salts thereof as an active ingredient. The pharmaceutical composition of the present invention may be used in the form of eye drops.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: November 26, 2019
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Kyu-Yang Yi, Sung-Eun Yoo, Nack-Jeong Kim, Jee-Hee Suh, Choun-Ki Joo, Jun-Sub Choi, Jae-Sik Yang, Geun-Hyeog Lee, Yun-Seok Cho, Jin-Ha Park, Hye-Sung Lee
  • Patent number: 10403415
    Abstract: In a transparent electrode based on a metal material having reduced light reflectance, a light absorbing layer having black characteristic is formed on a lower surface, a partition wall, and/or an upper surface of a metal wire, and thus, light reflectance of transparent electrode is minimized. In a method of manufacturing a transparent electrode, the light absorbing layer can be selectively formed on the upper and lower surfaces and the partition wall of the metal wire having a fine line width by using self-aligning and a spontaneous pattern effect. A conductive wire is implemented by using an imprinting process using an elastic body-based stamp, and thus, conductive wires having a fine line width and an excellent aspect ratio can be formed, so that it is possible to improve electric conductivity and transmittance.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: September 3, 2019
    Assignee: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Hak-Rin Kim, Ji-Sub Park, Jun-Chan Choi
  • Publication number: 20190241108
    Abstract: A leg rest having a distortion preventing function, according to the present disclosure, includes: a fixed bracket fixedly provided at the front of the lower end of a vehicle seat frame; a rotating bracket provided at the front of the fixed bracket so as to be rotatable in a vertical direction; a driving unit connected to the lower surface of the rotating bracket so as to rotate the rotating bracket; a tilting unit respectively supporting both sides of the rotating bracket so as to intermediate between the fixed bracket and the rotating bracket, and tilting the rotating bracket in the longitudinal direction of the fixed bracket; and a link bracket intermediating between the driving unit and the tilting unit so as to prevent horizontal distortion when the rotating bracket rotates.
    Type: Application
    Filed: April 16, 2019
    Publication date: August 8, 2019
    Applicant: HYUNDAI TRANSYS INCORPORATED
    Inventors: Jun Kyu KIM, Myeong Sub KIM, Gi Tae JO, Yeon Min CHOI
  • Publication number: 20190177690
    Abstract: The present invention relates to a method for culturing corneal stem cell-like cell lines by inducing differentiation of induced pluripotent stem cells (iPSC). The method comprises the following steps: preparing a basal medium comprising DMEM F12, L-ascorbic acid, sodium selenite, and sodium chloride; adding additives for culturing induced pluripotent stem cells to the basal medium; preparing a feeder free culture medium by coating the basal medium with Vitronectin recombinant human protein; adding induced pluripotent stem cells to the feeder free culture medium and culturing them; adding additives for creating an environment for stem cell growth to the feeder free culture medium; adding BMP4 and Wnt3a sequentially to the feeder free culture medium in order to induce differentiation of the induced pluripotent stem cells into corneal stem cell-like cell lines; and culturing the cells differentiated from the induced pluripotent stem cells in PI culture fluid.
    Type: Application
    Filed: August 4, 2017
    Publication date: June 13, 2019
    Inventors: Choun Ki JOO, Jee Won MOK, Hee Jung JU, Jun Sub CHOI
  • Patent number: 10279046
    Abstract: The present invention relates to a composition for treating an ocular inflammatory disease, comprising hydrophilic sulfasalazine and hyaluronic acid, and a preparation method therefor. Furthermore, the present invention relates to a method for treating an ocular inflammatory disease, which comprises administering, to an individual, a therapeutically effective amount of hydrophilic sulfasalazine and hyaluronic acid.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: May 7, 2019
    Assignee: CATHOLIC UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Choun-Ki Joo, Jun-Sub Choi
  • Publication number: 20180221343
    Abstract: The present invention provides a pharmaceutical composition for preventing or treating macular degeneration, which comprises benzopyran derivatives substituted with secondary amines including imidazole or pharmaceutically acceptable salts thereof as an active ingredient. The pharmaceutical composition of the present invention may be used in the form of eye drops.
    Type: Application
    Filed: March 30, 2018
    Publication date: August 9, 2018
    Applicants: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
    Inventors: Kyu-Yang YI, Sung-Eun YOO, Nack-Jeong KIM, Jee-Hee SUH, Choun-Ki JOO, Jun-Sub CHOI, Jae-Sik YANG, Geun-Hyeog LEE, Yun-Seok CHO, Jin-Ha PARK, Hye-Sung LEE
  • Patent number: 9969771
    Abstract: Provided are a tetrapeptide for inhibiting VEGF-induced angiogenesis and a use thereof, and particularly, provided is a peptide having the amino acid sequence of R-X1-X2-E (wherein X1 is leucine (L), isoleucine (I) or valine (V), and X2 is tyrosine (Y) or phenylalanine (F)) for inhibiting angiogenesis, or preventing, improving or treating cancer. This research was supported by grants from the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea, in 2011 and 2013 [NRF-2011-0028790 and 2013M3A9B6046563]. The tetrapeptide may effectively inhibit VEGF-induced angiogenesis or growth of cancer cells without a risk of side effects, and therefore may be expected to exhibit an excellent anticancer effect.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: May 15, 2018
    Assignee: AVIXGEN INC.
    Inventors: Young Myeong Kim, Yi Yong Baek, Dong Keon Lee, Jun-Sub Choi, Min Jung Kim, Hye Cheong Koo
  • Publication number: 20170274005
    Abstract: Disclosed is a complex for remedying or treating a retinal disease. The complex includes a hyaluronic acid or a derivative thereof, a carbon nanomaterial covalently bonded to the hyaluronic acid or the derivative thereof, and a photosensitizer bonded to the carbon nanomaterial. The complex for remedying or treating the retinal disease according to the present invention includes a hyaluronic acid-carbon nanomaterial-photosensitizer complex, thus selectively preventing the formation of active oxygen in retinal pigment epithelium cells for a relatively long period of time. Accordingly, the complex has excellent therapeutic efficacy and easily infiltrates into cells. Further, the present invention provides a composition for remedying or treating a retinal disease including the hyaluronic acid-carbon nanomaterial-photosensitizer complex.
    Type: Application
    Filed: December 20, 2016
    Publication date: September 28, 2017
    Inventors: Sei Kwang HAHN, Songeun Beack, Jun-Sub Choi, Choun-Ki Joo
  • Publication number: 20160193234
    Abstract: The present invention relates to a composition for treating an ocular inflammatory disease, comprising hydrophilic sulfasalazine and hyaluronic acid, and a preparation method therefor. Furthermore, the present invention relates to a method for treating an ocular inflammatory disease, which comprises administering, to an individual, a therapeutically effective amount of hydrophilic sulfasalazine and hyaluronic acid.
    Type: Application
    Filed: March 6, 2014
    Publication date: July 7, 2016
    Inventors: Choun-Ki JOO, Jun-Sub CHOI
  • Patent number: 9364552
    Abstract: The present invention relates to a composition for inhibiting after-cataract including a hydrophilic sulfasalazine; a high content of hyaluronic acid; and a carrier containing an aqueous solution, and a method of preparing a composition for inhibiting after-cataract including the steps of adding hyaluronic acid powder to a hydrophilized sulfasalazine; and mixing the same with a specific condition.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: June 14, 2016
    Assignees: BMI KOREA CO., LTD, CATHOLIC UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Yeong-Jun Baik, Choun-Ki Joo, Sung-Hee Lee, Jun-Sub Choi, Koo Woo
  • Publication number: 20140378410
    Abstract: The present invention relates to a composition for inhibiting after-cataract including a hydrophilic sulfasalazine; a high content of hyaluronic acid; and a carrier containing an aqueous solution, and a method of preparing a composition for inhibiting after-cataract including the steps of adding hyaluronic acid powder to a hydrophilized sulfasalazine; and mixing the same with a specific condition.
    Type: Application
    Filed: January 9, 2012
    Publication date: December 25, 2014
    Applicants: BMI Korea co., Ltd., CATHOLIC UNIVERSITY INDUSTRY-ACADEMIC COOPERATION
    Inventors: Yeong-Jun Baik, Choun-Ki Joo, Sung-Hee Lee, Jun-Sub Choi, Koo Woo
  • Patent number: 8895069
    Abstract: The present invention relates to a drug delivery composition comprising a hyaluronic acid-peptide conjugate micelle and a production method thereof. According to the drug delivery composition and the production method of the drug-loaded, hyaluronic acid-peptide conjugate micelle of the present invention, the reaction for encapsulating can proceed in a mixed solvent of an aqueous solvent and an organic solvent. Therefore, the present invention can be applied to various types of water-insoluble active components and the biocompatible and biodegradable derivative can encapsulate a drug to provide a drug-loaded micelle, which is safe to be applied for human bodies. Moreover, the micelle has a therapeutic effect from the peptide contained therein, which can act in combination with the drug as packing therein. Therefore, the drug delivery composition and its production method can be utilized in the field of producing a sustained release formulation with an extended duration of the medicinal effect.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: November 25, 2014
    Assignee: Postech Academy-Industry Foundation
    Inventors: Sei Kwang Hahn, Choun-Ki Joo, Yoon Keun Kim, Seung Kew Yoon, Eun Ju Oh, Ki Su Kim, Hyemin Kim, Kitae Park, Jeong-A Yang, Jun-Sub Choi, You Me Tae, Wonhee Hur
  • Publication number: 20140018402
    Abstract: The present invention provides a pharmaceutical composition for preventing or treating macular degeneration, which comprises benzopyran derivatives substituted with secondary amines including imidazole or pharmaceutically acceptable salts thereof as an active ingredient. The pharmaceutical composition of the present invention may be used in the form of eye drops.
    Type: Application
    Filed: March 29, 2011
    Publication date: January 16, 2014
    Applicants: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Kyu-Yang Yi, Sung-Eun Yoo, Nack-Jeong Kim, Jee-Hee Suh, Choun-Ki Joo, Jun-Sub Choi, Jae-Sik Yang, Geun-Hyeog Lee, Yun-Seok Cho, Jin-Ha Park, Hye-Sung Lee
  • Publication number: 20120294945
    Abstract: The present invention relates to a drug delivery composition comprising a hyaluronic acid-peptide conjugate micelle and a production method thereof. According to the drug delivery composition and the production method of the drug-loaded, hyaluronic acid-peptide conjugate micelle of the present invention, the reaction for encapsulating can proceed in a mixed solvent of an aqueous solvent and an organic solvent. Therefore, the present invention can be applied to various types of water-insoluble active components and the biocompatible and biodegradable derivative can encapsulate a drug to provide a drug-loaded micelle, which is safe to be applied for human bodies. Moreover, the micelle has a therapeutic effect from the peptide contained therein, which can act in combination with the drug as packing therein. Therefore, the drug delivery composition and its production method can be utilized in the field of producing a sustained release formulation with an extended duration of the medicinal effect.
    Type: Application
    Filed: December 15, 2011
    Publication date: November 22, 2012
    Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Sei Kwang HAHN, Choun-Ki Joo, Yoon Keun Kim, Seung Kew Yoon, Eun Ju Oh, Ki Su Kim, Hyemin Kim, Kitae Park, Jeong-A Yang, Jun-sub Choi, You Me Tae, Wonhee Hur
  • Patent number: 8242094
    Abstract: The present invention relates to a siRNA which targets mRNA of the NF-Kappa B p105 gene to cause its degradation by RNAi induction. In addition, the present invention provides a pharmaceutical composition for the treatment of diseases associated with aberrant cell proliferation and migration, comprising the siRNA and delivery vehicle capable of intracellular delivery of the same.
    Type: Grant
    Filed: August 22, 2008
    Date of Patent: August 14, 2012
    Assignee: Biopolymed, Inc.
    Inventors: Myung-Ok Park, Choun-Ki Joo, Jun-Sub Choi, Kyung-A Kim, Sung-Sik Bang
  • Publication number: 20110280929
    Abstract: The present invention relates to a siRNA which targets mRNA of the NF-Kappa B p105 gene to cause its degradation by RNAi induction. In addition, the present invention provides a pharmaceutical composition for the treatment of diseases associated with aberrant cell proliferation and migration, comprising the siRNA and delivery vehicle capable of intracellular delivery of the same.
    Type: Application
    Filed: August 22, 2008
    Publication date: November 17, 2011
    Inventors: Myung-Ok Park, Choun-Ki Joo, Jun-Sub Choi, Kyung-A Kim, Sung-Sik Bang